Structural pharmacology and therapeutic potential of 5-methoxytryptamines.
Level 5 - mechanism / opinion, no new human data
Bench structural biology (cryo-EM) and preclinical rodent behavioral models without human clinical data.
PubMed 38720072 · doi:10.1038/s41586-024-07403-2
What was done
The authors determined five cryogenic electron microscopy (cryo-EM) structures of the serotonin 5-HT1A receptor bound to 5-methoxytryptamines (including 5-MeO-DMT) and compared them to complexes with LSD and clinically used 5-HT1A agonists. They combined structure-activity relationship analyses and receptor mutagenesis at 5-HT1A and 5-HT2A with in vivo mouse behavioral assays to assess hallucinogenic-like, anxiolytic-like, and antidepressant-like responses in socially defeated mice.
What was found
The abstract reports no exact quantitative values, effect sizes, or statistical metrics. Structurally, the authors identified determinants of 5-HT1A signaling potency, efficacy, and selectivity relative to 5-HT2A. In mouse behavioral models, a 5-HT1A-selective 5-MeO-DMT analogue lacked hallucinogenic-like effects while preserving anxiolytic-like and antidepressant-like activity.
Why it matters
This study provides structural insights into how 5-methoxytryptamines engage 5-HT1A receptors and shows that hallucinogenic-like and therapeutic-like effects can be decoupled through selective agonist design.
Limits
The study is entirely preclinical, relying on in vitro structural biology, mutagenesis, and rodent behavioral paradigms, which may not translate directly to human pharmacology or neuropsychiatric outcomes. The abstract does not disclose animal sample sizes, effect magnitudes, or statistical precision.
Cited by
- supports 5-MeO-DMT is a serotonin tryptamine chemically similar to psilocybin and DMT.